{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:17:26Z","timestamp":1793657846772,"version":"4.5.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA087723"],"award-info":[{"award-number":["K12CA087723"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jlb.2025.100442","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:14:07Z","timestamp":1761696847000},"page":"100442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7860-8417","authenticated-orcid":false,"given":"Christian D.","family":"Rolfo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moh'd M.","family":"Khushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5403-0916","authenticated-orcid":false,"given":"Roberto","family":"Borea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Herrman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin R.","family":"Espenschied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle J.","family":"Medford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jlb.2025.100442_bib1","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3390\/cancers16142597","article-title":"Chemotoxicity and associated risk factors in colorectal cancer: a systematic review and meta-analysis","volume":"16","author":"Han","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jlb.2025.100442_bib2","series-title":"Advances in cancer research","first-page":"1","article-title":"Chapter one - an overview of chemotoxicity and radiation toxicity in cancer therapy","volume":"vol. 155","author":"Yazbeck","year":"2022"},{"issue":"1","key":"10.1016\/j.jlb.2025.100442_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/cancers14010127","article-title":"Prediction of chemotoxicity, unplanned hospitalizations and early death in older patients with colorectal cancer treated with chemotherapy","volume":"14","author":"Feliu","year":"2021","journal-title":"Cancers"},{"issue":"3\u20134","key":"10.1016\/j.jlb.2025.100442_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1142\/S2339547818300020","article-title":"The growing role of precision and personalized medicine for cancer treatment","volume":"6","author":"Krzyszczyk","year":"2018","journal-title":"Technology"},{"issue":"6551","key":"10.1016\/j.jlb.2025.100442_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/bmj.293.6551.871","article-title":"Cytotoxic chemotherapy for common adult malignancies: \u201cthe emperor's new clothes\u201d revisited?","volume":"293","author":"Kearsley","year":"1986","journal-title":"Br Med J Clin Res Ed"},{"issue":"8","key":"10.1016\/j.jlb.2025.100442_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clon.2004.06.007","article-title":"The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies","volume":"16","author":"Morgan","year":"2004","journal-title":"Clin Oncol"},{"issue":"23","key":"10.1016\/j.jlb.2025.100442_bib7","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"15","key":"10.1016\/j.jlb.2025.100442_bib8","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal Tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"10.1016\/j.jlb.2025.100442_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00299","article-title":"Prospective clinical validation of the InVisionFirst-Lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous Non\u2013small-cell lung cancer","author":"Pritchett","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2025.100442_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtho.2018.10.008","article-title":"Hybrid capture\u2013based genomic profiling of circulating tumor DNA from patients with advanced non\u2013small cell lung cancer","volume":"14","author":"Schrock","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.jlb.2025.100442_bib11","first-page":"1647","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.jlb.2025.100442_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group","author":"Pascual","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2025.100442_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2025.100442_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51679","article-title":"Concurrent circulating tumor DNA and tissue genotyping\u2014ready for prime time?","volume":"7","author":"Bleiberg","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jlb.2025.100442_bib15","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.jlb.2025.100442_bib16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2025.100442_bib17","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3467","article-title":"Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers","author":"Parikh","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jlb.2025.100442_bib18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12916-023-03017-z","article-title":"Potential value of ctDNA monitoring in metastatic HR +\/HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial","volume":"21","author":"Chiu","year":"2023","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.jlb.2025.100442_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.jlb.2025.100442_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-021-00218-8","article-title":"Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4\/6 inhibition and endocrine therapy","volume":"7","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"Npj Breast Cancer"},{"issue":"11","key":"10.1016\/j.jlb.2025.100442_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jlb.2025.100442_bib22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-Based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jlb.2025.100442_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005924","article-title":"Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy","volume":"11","author":"Sivapalan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jlb.2025.100442_bib24","article-title":"Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"6","author":"Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.jlb.2025.100442_bib25","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jlb.2025.100442_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-Based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.jlb.2025.100442_bib27","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","article-title":"Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non\u2013small cell lung cancer","volume":"29","author":"Pellini","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jlb.2025.100442_bib28","first-page":"1","article-title":"Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer","volume":"8","author":"Boscolo Bragadin","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"3","key":"10.1016\/j.jlb.2025.100442_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40487-024-00287-2","article-title":"Dynamic changes in circulating tumor fraction as a predictor of real-world clinical outcomes in solid tumor malignancy patients treated with immunotherapy","volume":"12","author":"Gentzler","year":"2024","journal-title":"Oncol Ther"},{"key":"10.1016\/j.jlb.2025.100442_bib30","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","author":"Gouda","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7_Supplement","key":"10.1016\/j.jlb.2025.100442_bib31","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-2299","article-title":"Abstract 2299: misclassification of clonal hematopoietic mutations as tumor-derived confound accurate ctDNA-response assessment in patients with metastatic non-small-cell lung cancer: analyses from the phase 3 MYSTIC trial","volume":"83","author":"Abbosh","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jlb.2025.100442_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","article-title":"Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study\u2606","volume":"34","author":"Reichert","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jlb.2025.100442_bib33","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2025.100442_bib34","article-title":"Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples","volume":"6","author":"Husain","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2025.100442_bib35","article-title":"Pan-cancer prevalence of microsatellite instability-high (MSI-H) identified by circulating tumor DNA and associated real-world clinical outcomes","volume":"7","author":"Kasi","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jlb.2025.100442_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e19135","article-title":"Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group","volume":"38","author":"Walker","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jlb.2025.100442_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/CCI.20.00125","article-title":"Comparisons of real-world time-to-event end points in oncology research","author":"Walker","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"issue":"3","key":"10.1016\/j.jlb.2025.100442_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced Non\u2013small-cell lung cancer","author":"Stewart","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.jlb.2025.100442_bib39","first-page":"716","article-title":"Validation of real-world data-based endpoint measures of cancer treatment outcomes","volume":"2021","author":"Li","year":"2022","journal-title":"AMIA Annu Symp Proc"},{"issue":"12_Supplement","key":"10.1016\/j.jlb.2025.100442_bib40","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1158\/1538-7445.AM2022-4089","article-title":"Abstract 4089: time to treatment discontinuation and time to next treatment as proxies of real-world progression-free survival in breast cancer patients","volume":"82","author":"Izano","year":"2022","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jlb.2025.100442_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/1078-0432.CCR-24-0924","article-title":"Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy","volume":"31","author":"Ghidini","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jlb.2025.100442_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00216","article-title":"Early circulating tumor DNA shedding kinetics for prediction of platinum sensitivity in patients with small cell lung cancer","author":"Murciano-Goroff","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.jlb.2025.100442_bib43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non\u2013small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jlb.2025.100442_bib44","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.jlb.2025.100442_bib45","first-page":"OF1","article-title":"ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: findings from an aggregate analysis of eight clinical trials","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jlb.2025.100442_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jlb.2025.100442_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-023-02445-1","article-title":"Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors","author":"Thompson","year":"2023","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.jlb.2025.100442_bib48","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2024012929","article-title":"Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes","volume":"8","author":"Nead","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jlb.2025.100442_bib49","doi-asserted-by":"crossref","unstructured":"Takahashi K, Nakada D, Goodell M. Distinct landscape and clinical implications of therapy-related clonal hematopoiesis. doi:10.1172\/JCI180069.","DOI":"10.1172\/JCI180069"},{"issue":"11","key":"10.1016\/j.jlb.2025.100442_bib50","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.jlb.2025.100442_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/jmp2030022","article-title":"Liquid biopsy for biomarker testing in non-small cell lung cancer: a European perspective","volume":"2","author":"Malapelle","year":"2021","journal-title":"J Mol Pathol"},{"issue":"8","key":"10.1016\/j.jlb.2025.100442_bib52","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/2767-9764.CRC-25-0151","article-title":"Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study","volume":"5","author":"Liang","year":"2025","journal-title":"Cancer Res Commun"}],"updated-by":[{"DOI":"10.1016\/j.jlb.2025.100448","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000}},{"DOI":"10.1016\/j.jlb.2025.100448","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195425001584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195425001584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:58:53Z","timestamp":1773280733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195425001584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"alternative-id":["S2950195425001584"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2025.100442","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2025.100442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100442"}}